FDA Approves Mitochondrial Therapy for Bill Ackman's Daughter; Novo Nordisk Rebrands
The FDA approves innovative mitochondrial therapy for Bill Ackman's daughter, Novo Nordisk rebrands to Novo, Pfizer enforces vaccine debt, and RedDress advances wound care.
The U.S. Food and Drug Administration (FDA) has approved an innovative mitochondrial therapy for Lucy, the daughter of billionaire investor Bill Ackman, following a severe stroke that left her in a coma. Ackman shared the milestone on X, noting that his daughter emerged from the coma against medical odds and is now seeking global scientific input to restore her vision.
Mitochondrial Transplant and Clinical Trials
Last May, the FDA authorized an experimental procedure involving the injection of autologous mitochondria—extracted from Lucy's leg muscle—directly into her eyes. Preliminary findings from the trial were published in August on Research Square, indicating no inflammatory response and restored pupillary light reflexes following the procedure.
Mitochondria, the cellular organelles responsible for energy production, have increasingly become the focus of longevity research and genetic therapies. While large-scale commercial treatments remain unapproved, compassionate use cases in pediatric cardiology have yielded intriguing initial results using similar autologous methods.
Retinal Recovery and Future Outlook
Ackman explained that Lucy's vision impairment likely stems from neural damage deep within the retina. Although the initial pupillary response improvements plateaued weeks after the injection, they remained significantly above baseline levels. The next phase of research aims to derive mitochondria from stem cells rather than muscle biopsies.
In the interim, rehabilitative therapy has resulted in measurable improvements, allowing Lucy to track objects visually even in low-light conditions. The family continues to explore advanced interventions globally.
Novo Nordisk Drops 'Nordisk' in Strategic Rebranding
Following in the footsteps of mononymous cultural icons, Danish pharmaceutical giant Novo Nordisk has announced it is dropping the "Nordisk" moniker to rebrand simply as "Novo." The strategic shift comes as the pioneer of blockbuster weight-loss therapies navigates increased competition from Eli Lilly and recent setbacks in clinical trials.
Under CEO Mike Doustdar, the company has undertaken major restructuring efforts. The removal of "Nordisk," which translates to "Nordic," signals a deliberate move toward a more international consumer profile. While financial analysts and the Danish public have reacted with cautious indifference—often pointing to stock performance rather than nomenclature—the company insists the change reflects a broader corporate evolution.
Pfizer Pursues Legal Enforcement Against Poland and Romania
Pharmaceutical multinational Pfizer has initiated aggressive legal measures to recover $2.2 billion from Poland and Romania for COVID-19 vaccine doses ordered collectively by the European Union during the pandemic. Following a Belgian EU court ruling affirming the binding nature of the multi-year procurement contracts, Pfizer began intercepting EU aviation safety tax revenues allocated to the member states.
The enforcement action has severely impacted national aviation authorities, threatening up to 80% of Poland's aviation safety funding and prompting salary reductions in Romania. Both nations have appealed the Brussels tribunal's decisions, arguing that geopolitical shifts and economic pressures resulting from the war in Ukraine rendered the original financial commitments untenable.
RedDress Advances Complex Wound Healing Technology
Israeli biomedical firm RedDress has announced successful clinical trial results for its proprietary wound-healing technology, which utilizes biological blood clots derived from the patient's own blood. Tested on 11 patients with complex, non-healing wounds—including cranial injuries with exposed bone—the bio-scaffold treatment provides an alternative where traditional skin grafts are unviable.
Founded and led by Alon Kushnir, RedDress secured $26 million in a 2023 funding round backed by ATHOS Biopharma, HCS Capital, and Ragnar Crossover Fund, bringing its total capital raise to approximately $43 million. The company's core product is already cleared for commercial distribution in the United States.
